Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28199018 | 1.00 | DGAT1 (0.36) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL4939145 | 0.86 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL28195825 | 0.86 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL9116850 | 0.86 | DGAT1 (0.40) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL25436173 | 0.82 | DGAT1 (0.38) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL2330290 | 0.82 | DGAT1 (0.38) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL30185755 | 0.82 | DGAT1 (0.38) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL28815007 | 0.81 | DGAT1 (0.36) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL1536326 | 0.79 | DGAT1 (0.39) | DGAT1CYP1A2CYP2D6 | |
| SCHEMBL27797420 | 0.79 | DGAT1 (0.35) | DGAT1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | DOMPE PHA.R.MA S.P.A. (IT) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045522-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | C5AR2, C3AR1, C5AR1 | DGAT1 360/4885CYP1A2 348/4885CYP2D6 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.